Exagen says systematic review finds AVISE Lupus test flags 25% of SLE cases missed by standard serology
PUBT · 06/01 13:02
Share
Listen to the news
- Exagen announced publication of a systematic review validating real-world performance of its AVISE Lupus diagnostic algorithm; results have already been published.
- The review found the test improved identification of systemic lupus patients versus conventional blood markers, supporting earlier, more confident diagnosis.
- Findings were consistent across studies spanning 2011-2025, reinforcing the product’s clinical positioning for broader adoption.
- Exagen said the expanded evidence base supports its reimbursement strategy and premium market positioning in autoimmune diagnostics.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exagen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010900PRIMZONEFULLFEED9729321) on June 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved